Literature DB >> 24299222

Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.

C Treloar1, J Rance, G J Dore, J Grebely.   

Abstract

Provision of hepatitis C virus (HCV) assessment and treatment via opioid substitution treatment (OST) clinics has been posed as an effective means of engaging populations with high HCV prevalence. This study explores OST client and health professional reports concerning barriers and facilitators affecting the delivery and uptake of HCV care and treatment within OST settings. In-depth interviews were conducted with 57 clients, 16 staff from four NSW clinics participating in the Australian ETHOS study and three peer workers. Client participants included those who had not had HCV assessment; those who had HCV assessment only; and those who were awaiting or undertaking HCV treatment. A clear difference in decisions about HCV treatment emerged between participant groups. For those who have not been assessed, barriers to engaging with HCV care included the perception that they were physically well, were not experiencing HCV symptoms, had other life priorities and were concerned about the side effects and tolerability of treatment. Those who had engaged with care expressed motivations stemming from seeing friends becoming unwell, wanting to live longer and hearing positive stories of treatment. For those interested in HCV treatment, issues related to both provider and setting were important, such as presence of an engaged clinician, an accessible treatment pathway and availability of support. In this integrated care model, some barriers to HCV care and treatment (particularly those relating to health provider and the system) are minimized. In this setting, HCV treatment remained an unattractive option for a significant number of clients. Providing ways for those without HCV symptoms to be assessed for liver damage may be important to open up alternative conversations about HCV care. Further, the importance of a changing discourse of treatment is apparent from these data and could be enhanced by peer communication that provides information about successful treatment experiences.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis C; opiate substitution treatment; qualitative research; treatment

Mesh:

Year:  2013        PMID: 24299222     DOI: 10.1111/jvh.12183

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  12 in total

1.  Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.

Authors:  Jason Grebely; Lucy Tran; Louisa Degenhardt; Alexander Dowell-Day; Thomas Santo; Sarah Larney; Matthew Hickman; Peter Vickerman; Clare French; Kerryn Butler; Daisy Gibbs; Heather Valerio; Phillip Read; Gregory J Dore; Behzad Hajarizadeh
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

2.  Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.

Authors:  Alison D Marshall; Sahar Saeed; Lisa Barrett; Curtis L Cooper; Carla Treloar; Julie Bruneau; Jordan J Feld; Lesley Gallagher; Marina B Klein; Mel Krajden; Naglaa H Shoukry; Lynn E Taylor; Jason Grebely
Journal:  CMAJ Open       Date:  2016-10-14

3.  Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.

Authors:  Diana Hernández; Daniel J Feaster; Lauren Gooden; Antoine Douaihy; Raul Mandler; Sarah J Erickson; Tiffany Kyle; Louise Haynes; Robert Schwartz; Moupali Das; Lisa Metsch
Journal:  AIDS Behav       Date:  2016-01

4.  HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

Authors:  Sofia R Bartlett; Brendan Jacka; Rowena A Bull; Fabio Luciani; Gail V Matthews; Francois M J Lamoury; Margaret E Hellard; Behzad Hajarizadeh; Suzy Teutsch; Bethany White; Lisa Maher; Gregory J Dore; Andrew R Lloyd; Jason Grebely; Tanya L Applegate
Journal:  Infect Genet Evol       Date:  2015-11-26       Impact factor: 3.342

5.  "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.

Authors:  Manuela Rasi; Patrizia Künzler-Heule; Patrick Schmid; David Semela; Philip Bruggmann; Jan Fehr; Susi Saxer; Dunja Nicca
Journal:  BMC Infect Dis       Date:  2014-09-18       Impact factor: 3.090

6.  Access to substance use treatment among young adults who use prescription opioids non-medically.

Authors:  Elliott J Liebling; Jesse L Yedinak; Traci C Green; Scott E Hadland; Melissa A Clark; Brandon D L Marshall
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-11-29

7.  Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia.

Authors:  Annie Madden; Max Hopwood; Joanne Neale; Carla Treloar
Journal:  Harm Reduct J       Date:  2018-08-15

Review 8.  Families Living with Blood-Borne Viruses: The Case for Extending the Concept of "Serodiscordance".

Authors:  Asha Persson; Christy E Newman; Myra Hamilton; Joanne Bryant; Jack Wallace; Kylie Valentine
Journal:  Interdiscip Perspect Infect Dis       Date:  2017-10-18

9.  Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.

Authors:  Alain H Litwin; Martine Drolet; Chizoba Nwankwo; Martha Torrens; Andrej Kastelic; Stephan Walcher; Lorenzo Somaini; Emily Mulvihill; Jochen Ertl; Jason Grebely
Journal:  J Viral Hepat       Date:  2019-06-11       Impact factor: 3.728

Review 10.  Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy Among Women with Substance Use Disorders.

Authors:  Kirsten I Black; Carolyn A Day
Journal:  Subst Abuse       Date:  2016-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.